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Insulin-like growth factors (IGFs) and IGF binding proteins, serum
acid-labile subunit and growth hormone binding protein in nephrotic
children. We hypothesized that the increased glomerular permeability to
serum proteins in the nephrotic syndrome might lead to alterations of the
somatotropic hormone axis, thereby contributing to growth failure and
catabolism in the nephrotic state. The insulin-like growth factors (IGF)-I
and -II and the IGF binding proteins (IGFBP)-1, -2 and -3 were analyzed
in serum and urine of 21 children with the nephrotic syndrome and normal
glomerular filtration rate. Mean age-related serum IGF-I levels by RIA
(—0.53 0.34 SD) were slightly, but significantly (P < 0.05) decreased
compared with the reference population, whereas mean age-related serum
IGF-II levels (0.68 0.21 SD) were slightly, but significantly (P < 0.005)
increased. The urinary excretion rate of both peptides was enhanced
fivefold. By RIA, mean age-related serum IGFBP-1 (2.05 0.19 SD) and,
even more pronounced, IGFBP-2 (5.97 0.65 SD) were clearly elevated
despite a 12-fold and 2-fold increase of the respective urinary excretion
rate. There was a tight and specific correlation between age-related serum
IGFBP-2 levels and the degree of the nephrotic syndrome, as estimated by
serum albumin levels (r =
—0.78, P < 0.0001). Serum immunoreactive
IGFBP-3 levels were also elevated (1.79 0.33 SD) in nephrotic serum,
due to an increase of low-molecular weight IGFBP-3 fragments. By FPLC
analysis, there was a decrease of the 150 kDa IGFBP ternary complex in
nephrotic serum, which in the presence of normal concentrations of the
acid-labile subunit by RIA appears to be due to a reduction of intact
IGFBP-3. Serum levels of the high-affinity GH binding protein that
presumably reflects GH receptor status in tissues were normal. In
summary, total serum IGFs in children with the nephrotic syndrome are
normal, but the binding of IGFs to IGFBPs in the circulation is altered
with a shift from the 150 kDa IGFBP complex to an excess of low
molecular weight IGFBPs. Because increased unsaturated high-affinity
IGFBPs in ncphrotic serum have the ability to inhibit IOF action on target
tissues by competing with the type 1 IOF receptor for TGF binding, this
alteration is likely to contribute to growth failure and tissue catabolism in
the nephrotic state.
Prior to the introduction of glucocorticoid therapy, growth
retardation and reduced tissue anabolism was frequently observed
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in children with the nephrotic syndrome, and this remains a
problem in glucocorticoid-resistant nephrotic syndrome [1]. Mul-
tiple pathogenic mechanisms are involved such as protein-calorie
malnutrition secondary to poor appetite, malabsorption due to
edema of the gastrointestinal tract and, in particular, protein
losses in the urine due to increased glomerular permeability to
plasma proteins. This alteration is likely to lead to secondary
alterations of the somatotropic hormone axis that might contrib-
ute to growth failure and reduced tissue anabolism in the ne-
phrotic state.
The insulin-like growth factors (IGFs) are a unique family of
polypeptide hormones with strong mitogenic and anabolic prop-
erties. IGFs in biological fluids are complexed to high-affinity IGF
binding proteins (IGFBPs), six of which have been identified. The
IGFBPs regulate the action of IGFs by prolonging their half-lives,
directing their distribution, and modulating the interaction with
their respective receptors [21. Each of the IGFBPs exhibits
differential regulatory mechanisms involving developmental, hor-
monal, and nutritional status. In the circulation, over 99% of IGFs
are tightly bound to IGFBPs [3]. IGFBP-3 is the predominant
circulating IGFBP in postnatal life. In contrast to the other
IGFBPs, it has the unique property to associate with an acid-labile
subunit (ALS) (Mr —85 kDa) after binding either IGF-I or
IGF-II. The subsequent constituted ternary complex is a high-
molecular weight complex of approximately 150 kDa [4]. Its
function is thought to act as a reservoir for the IGFs, preventing
rapid changes of free IGF levels. IGFBP-3 serum levels are
positively regulated by growth hormone (GH) secretory status [5].
It inhibits IOF action under some [61, but not all experimental
conditions [7—91. IGFBP-2 (32 kDa) is the second most abundant
TGFBP in the circulation and it binds to IGF-1I with a greater
affinity than IGF-I. IGFBP-i and IGFBP-2 inhibit IGF action
under many [10, Ii], but not all experimental conditions, appar-
ently by competing with IGF receptors for IGF binding. IGFBP-1
is a 28 kDa nonglycosylated protein that is primarily produced by
liver and female reproductive tissue [121. Insulin is the principal
suppressive regulator of hepatic IGFBP-1 production [12].
In the present study, we analyzed the IGF/IGFBP system in
serum and urine of children with active nephrotic syndrome.
Serum levels of ALS, the third component of the 150 kDa IGFBP
complex, were also examined. Moreover, we measured the levels
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Table 1. Patient characteristics
Proteinuria Creatinine
Duration of selective! clearance
Diagnosis Age years Height SDS BMI SDS
Serum albumin
giliter
Proteinuria
g/m2/day
proteinuria
days
non-
selective
mi/mini
1.73 m2
MCNS 7.6 1.1 —0.3 0.6 0.4 0.6 21.2 3.2 5.7 0.7 10 3 7/0 135 8.7
(N =7)
FSGS 8.1 1.7 —1.1 0.4° 0.3 0.4 21.9 1.9 10.8 1.4 959 176 4/3 123 13.5
(N =7)
MPGN 11.3 1.7 —0.7 0.4 0.6 0.7 29.5 1.9 4.1 1.0 969 463 0/4 114 9.0
(N =4)
HSP 10.1 2.4 —0.2 0.3 0.6 0.7 26.6 3.4 3.3 0.5 630 37 0/3 130 11.3
(N =3)
Total 9.0 0.8 —0.6 0.3° 0.4 0.3 23.7 1.5 6.9 0.9 592 135 11/10 126 5.7
(N = 21)
Data are mean SCM. Abbreviations are: MCNS, minimal change nephrotic syndrome; FSGS, focal segmental glomerulosclerosis; MPGN,
membranoproliferative glomerulonephritis; HSP, Henoch-Schonlein purpura glomerulonephritis; SDS, standard deviation score; BMI, body mass index.
a Significant difference between patients with the nephrotic syndrome and the reference population
of the high-affinity GH binding protein (GHBP) in nephrotic
serum. GHBP (Mr 60 kDa) is thought to reflect GH receptor
status in GH target tissues, because it is derived from the
extracellular domain of the GH receptor by proteolytic cleavage
[131. Our study is the first extensive analysis of the distal compo-
nents of the somatotropic hormone axis in children with the
nephrotic syndrome.
METHODS
Patients
Twenty-one children (11 boys/lO girls) with active nephrotic
syndrome were analyzed. Patient characteristics are listed in
Table 1. Height and weight were measured in all subjects with
standardized equipment and techniques. To estimate the nutri-
tional status of the patients, body mass index (BMI) was calcu-
lated using the formula: weight (kg)/height2 (m2) (Quetelet
index). To obtain age-independent estimates of body size and
mass, height and BMI (after logarithmic transformation to obtain
normally distributed data) were converted to SD score (SDS)
values related to age- and gender-specific means and SDS of
European reference populations [14, 151. The mean relative
height was slightly below the normal mean and the mean relative
BMI as an index of the nutritional status was normal (Table 1).
Seven children were studied during multiple relapses of the
nephrotic syndrome, resulting in a total number of 30 observa-
tions. All children had gross proteinuria and low serum albumin
levels (Table 1). Exclusion criteria were increased serum creati-
nine concentration for age, a decreased creatinine clearance
below < 80 ml/min/l.73 m2, or treatment with glucocorticoids,
angiotensin converting enzyme inhibitors or clonidin up to one
month prior to this study. Some patients were treated with
frusemide (N = 3) or hydrochlorothiazide (N = 4). The time of
onset of proteinuria was defined as the first day of documented
proteinuria by a dip stick test (Albustif°). Response to glucocor-
ticoid therapy was assessed according to the criteria of the
International Study Group of Kidney Disease in Children [16].
Blood samples were obtained in the morning in the fasting state.
Serum and 24-hour urine samples were stored at -—20°C until
analysis. For comparison, urine samples of 12 age- and gender-
matched healthy children (age 9.9 0.7 years) were analyzed.
Assays
IGF-I was measured by a novel IGFBP-blocked RIA utilizing a
specific high-affinity antiserum (gift of Drs. Breier and Gluckman,
Auckland, New Zealand) [17]. Details of the assay have been
published [18]. In brief, serum was diluted 1:150 with an acidic
phosphate buffer, to dissociate IGFs from IGFBPs. Concomi-
tantly with re-neutralization by adding the first antibody solution,
a large excess of IGF-II (25 ngltube) was added to block IGFBPs.
After addition of IGF-I tracer and incubation at 4°C for two days,
bound and free '251-IGF-I were separated by a second antibody
method [19]. There was an excellent parallelism between serial
dilutions of serum and recombinant IGF-I standard (Pharmacia
Upjohn, Stockholm, Sweden). Half-maximal displacement of
tracer occurred at 0.1 ngltube and sensitivity was 0.0081 ng. The
intra- and interassay coefficients of variation were 3.1 and 8.1%,
respectively. For measurement of urinary IGF-I, 300 il untreated
urine samples were acidified by adding 30 .tl 0.5 mol/liter phos-
phoric acid. One hundred microliters of these acidified samples
were then directly assayed for IGF-I by the IGFBP-blocked RIA.
Serum IGF-II was measured after acid-ethanol extraction using a
highly specific polyclonal antibody and blocking residual IGFBP
in the extract by an excess of IGF-I as described previously [19].
Urinary IGF-II was directly measured in acidified urine as de-
scribed for IGF-I. IGFBP was blocked by 25 ng IGF-I per tube.
IGFBP-1, IGFBP-2 and IGFBP-3 were measured by specific
RIAs that have been described in detail previously [20—22]. The
IGFBP-3 RIA recognizes both intact IGFBP-3 (Mr 45 kDa) as
well as low-molecular weight IGFBP-3 fragments [23]. Serum
samples were diluted 1:600, and unprocessed urine samples were
diluted 1:5 with an assay buffer before measurement. All samples
were assayed in duplicate. Both urinary IGFs and IGFBPs were
expressed as excretion rates normalized by body surface area.
For determination of the molecular size of IGFBP-3 and the
binding fraction of IGF-I in serum, 50 .tl of serum or concentrated
urine samples (about 1:100 using an Amicon ultrafiltration cell at
a molecular weight cut-off of 2000) were chromatographed at
room temperature over a Superose 12 column using a fast protein
liquid chromatography (FPLC) system (Pharmacia, Freiburg,
Germany). Fractions of 0.5 ml were collected at a rate of 1 mI/mm.
The elution was performed with 0.05 mol/liter sodium phosphate
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buffer, pH 7.4, containing 0.1 mol/liter NaCI, 0.1% BSA (wt:vol),
0.02% NaN5 (wt:vol). The fractions were assayed for IGFBP-3 by
RIA after 1:10 dilution with assay buffer.
For determination of serum protease activity towards recombi-
nant human (rh) IGFBP-3, sera of patients and controls were
diluted 1:10 with phosphate-buffered saline, pH 7.4. Five micro-
liters of resuspended 1251 [IGFBP-3] tracer (Diagnostic System
Laboratories, Houston, TX, USA), corresponding to —4000 cpm/
sl, were mixed with 5 jsl diluted serum from patients or controls
and incubated at 37°C for six hours, according to the recommen-
dations of the manufacturer. Ten microliters of Laemmli sample
buffer [24] were added to each sample. The samples were heated
at 94°C for five minutes and analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE, 12.5%) under
non-reducing conditions. The Kaleidoscope Prestained Standard
markers (Bio-Rad Lab., Hercules, CA, USA) were used as
markers. Gels were vacuum-dried immediately at 80°C and ex-
posed to X-ray films (Kodak, Tokyo, Japan) at —20°C.
ALS in serum was determined by a specific RIA, as described
previously [25]. The intra- and interassay coefficients of variation
were 3.4% and 6.5%, respectively. Serum GHBP was measured by
a ligand-mediated immunofunctional assay, as described previ-
ously [26]. The intra- and interassay coefficients of variation were
7% and 11%, respectively.
Serum albumin was analyzed by an autoanalyzer method.
Urinary protein concentration was determined by the Coomassie
method [27]. The selectivity of proteinuria was assessed by
analysis of the molecular mass of urinary proteins by SDS-PAGE
[28]. Selective proteinuria was defined by a Mr of urinary pro-
teins 60 kDa.
Statistical analysis
Reference values of serum levels for IGF-1, IGF-I1, IGFBP-3
[29], IGFBP-1, IGFBP-2 [30], ALS [25] and GI-IBP [31] in healthy
children of various ages have been published previously. The
distribution of these reference data are log normal. Measured
values were, therefore, transformed to their logarithms before
calculating SD scores (SDS) to obtain age-independent values for
comparison.
Data are given as mean SEM, if not indicated otherwise. Data
were examined for normal and non-Gaussian distribution by the
Shapiro-Wilk test. For comparison between two normally distrib-
uted groups the unpaired Student's t-test (two-tailed) was used.
For comparison of more than two normally distributed groups,
one-way analysis of variance followed by pairwise multiple com-
parisons (Student-Newman-Keuls method) was taken. For non-
normally distributed data, the nonparametric Wilcoxon signed
rank test or the Kruskal-WaIlis test were used. Correlations
between variables were assessed by univariate linear regression
analysis. P < 0.05 was accepted as statistically significant.
RESULTS
IGF and IGFBP serum levels
Individual serum IGF-l levels in patients with the nephrotic
syndrome related to the age-dependent normal range are de-
picted in Figure 1 A. IGF-I levels clustered in the low-normal
range; mean age-related serum IGF-I levels (—0.53 0.34 SD)
were slightly, but significantly reduced compared with the refer-
ence population (Table 2). In contrast, individual serum IGF-II
levels clustered in the high-normal range (Fig. 1B); mean age-
related serum IGF-II levels (0.68 0.21 SD) were slightly, but
significantly elevated compared with the reference population
(Table 2).
Individual serum IGFBP-1, -2, and -3 levels by RIA in children
with the nephrotic syndrome related to the age-dependent normal
range are shown in Figure 2. In the majority of patients, serum
IGFBP levels were clearly elevated above the upper normal range.
The increase of serum IGFBP-2 levels (5.97 0.65 SD) was
particularly striking, while IGFBP-1 and IGFBP-3 levels were
increased to a comparable extent (Table 2). Analysis of the
molecular size of serum IGFBP-3 by FPLC revealed an increase
of low-molecular weight IGFBP-3 fragments in nephrotic patients
and a decrease of the 150 kDa ternary complex (Fig. 3). We
sought to determine whether the increase of low molecular weight
IGFBP-3 fragments in nephrotic serum is due to increased
proteolytic activity towards IGFBP-3. Incubation of nephrotic
serum with rhIGFBP-3 did not result in a rapid degradation of the
binding protein (Fig. 4). In contrast, serum from late pregnancy
that was analyzed concomitantly as a positive control degraded
rhIGFBP-3 in our assay (Fig. 4), consistent with previous obser-
vations [32].
In controls, most of the immunoreactive serum IGF-I was
bound to the high-molecular weight IGFBP ternary complex (Fig.
5). In patients with the nephrotic syndrome, however, IGF-I was
preferably bound to low molecular weight IGFBPs.
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Fig. 1. Serum IGF-I (A) and IGF-II (B) levels
in children with active nephrotic syndrome
related to the age-dependent normal range. For
IGF-I the normal range is given by the 0.1, 5th,
50th, and 95th percentiles; for IGF-II it is given
by the 5th, 50th, and 95th percentiles. Closed
symbols indicate patients with serum albumin
levels below 25 g/liter, and open symbols above
25 g/liter.
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Table 2. Serum levels of IGFs, IGFBPs, ALS and GHBP in children with active nephrotic syndrome
Next, we sought to determine whether these alterations of
serum IGFs/IGFBPs are related to the degree of the nephrotic
syndrome. There was a tight inverse correlation of age-related
IGFBP-2 levels with serum albumin levels (r =
—0.78, P < 0.0001;
805
GHBP
(N = 21)
344 62
pmol/liter
0.41 0.37
SD
Fig. 3. Serum IGFBP-3 mol wt distribution by
FPLC analysis in normal serum (N = 5)
(straight line) and in three individual children
with active nephrotic syndrome. Nearly
identical results were obtained for the elution
profiles of serum IGFBP-3 in the five controls
tested (r = 0.998) and, therefore, only mean
values are shown. In normal serum,
immunoreactive IGFBP-3 eluted mainly at a
mol wt of —150 kDa, corresponding to the
ternary IGF-IGFBP-3-ALS complex. In
nephrotic serum, there was a decrease of the
IGFBP ternary complex and an increase of the
binary IGF-1GFBP-3 complex (40 to 50 kDa)
and of low molecular weight IGFBP-3
fragments.
IGF-1 IGF-1l IGFBP—1 IGFBP-2 IGFBP-3
Parameter (N = 30) (N = 27) (AT = 25) (N — 25) (N = 30) (N — 22)
Absolute serum 169 19 672 37 0.17 0.03 1.92 0.33 4.44 0.24 26.6 1.8
levels jrg/liter .tg/liter mg/liter mg/liter mg/liter mg/liter
Age-related —0.5 0.34 0.68 0.21 2.05 0.19 5.97 0.65 1.79 0.33 0.11 0.04
serum levels So SD SD SD SD SD
(SD score)
Statistics P < 0.05 P < 0.005 P < 0.0001 P < 0.0001 P < 0.0001 NS
Significant difference between patients with the nephrotie syndrome and the reference population. NS = not significant.
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Fig. 2. Serum IGFBP-1 (A), IGFBP-2 (B), and IGFBP-3 (C) levels in children with active nephrotic syndrome related to the respective age-dependent
normal range. The normal range is given by the 5th, 50th, and 95th percentiles. Closed symbols indicate patients with serum albumin levels below 25
g/liter and open symbols above 25 g/liter.
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Fig. 6) and a positive correlation of serum IGFBP-2 with the
degree of proteinuria (r = 0.43, P < 0.05). This correlation was
specific, because there was no relationship between serum albu-
min levels or the degree of proteinuria and the other components
— rr'
4rc
Fig. 4. A representative autoradiogram of
serum IGFBP-3 protease activity by 1251
IGFBP-3 degradation assay. By incubation of
rhIGFBP-3 with serum of late pregnancy (LP),
three different rhIGFBP-3 fragments were
observed (—32, 21, and 17 kDa). In nephrotic
serum (NS), there was no clear-cut increase of
protease activity towards rhIGFBP-3 compared
Ctr LP NS NS NS NS NS with control serum (ctr).
10
9
8
0
U)(I) 3
2
0
7
5
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Fraction number
of the IGF/IGFBP-axis. Neither the duration of the nephrotic
syndrome nor the selectivity of proteinuria, as estimated by SDS
PAGE, correlated with IGF or IGFBP serum levels. However,
patients with FSGS tended to have lower age-related 1GF-I levels
(—1.47 SDS) than patients with other types of nephrotic syn-
drome. Apart from that, IGF and JGFBP serum levels were
similar in the different histologic types of nephrotic syndrome.
Urinary excretion of IGF and IGFBP
Urinary excretion rates of IGF-I and IGF-II were increased
fivefold (Table 3). The ratio of IGF-1I over IGF-I in control urine
(14:1) was comparable to the ratio in patients with the nephrotic
syndrome (12:1). Also the urinary excretion rates of IGFBP-1
(12-fold), IGFBP-2 (2-fold), and IGFBP-3 (2-fold) were signifi-
cantly increased in nephrotic patients (Table 3). In urine of
patients and controls, only immunoreactive IGFBP-3 of less than
Fig. 5. Elution profiles of immunoreactive IGF-
I in normal serum (N = 5) (straight line) and
in three individual children with active
nephrotic syndrome. Nearly identical results
were obtained for the elution profiles of serum
IGF-I in the five controls tested (r = 0.98), and
therefore, only mean values are shown. In
control serum, most of the immunoreactive
serum IGF-I was bound to the 150 kDa IGFBP
ternary complex. In nephrotic serum, however,
IGF-I was preferably bound to low molecular
weight IGFBPs.
60 kDa were detected by FPLC analysis with a peak at 20 kDa
(Fig. 7). Urinary 1GF-1I (r = 0.55, P < 0.05) and IGFBP-3
excretion (r = 0.40, P < 0.05) correlated with the degree of
proteinuria. There was no correlation between serum levels of
IGFs or IGFBPs and their respective urinary excretion rates.
ALS and GHBP in serum
Age-related serum levels of ALS in children with active ne-
phrotic syndrome were normal (Fig. 8 and Table 2). There was a
tight correlation between serum ALS and IGFBP-3 levels (r =
0.76, P < 0.0001), as observed under normal conditions [25],
despite the fact that some of the IGFBP-3 in nephrotic serum was
present as low molecular weight IGFBP-3 fragments.
The concentration of the high affinity GHBP in nephrotic
serum was within the normal range (Table 2).
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Fig. 6. Age-related IGFBP-2 levels (SDS) as a function of serum albumin
levels (N = 23). There was a tight inverse correlation (r = —0.78, P <
0.000 1).
DISCUSSION
The present study is the first extensive analysis of the distal
components of the somatotropic hormone axis in patients with the
nephrotic syndrome. We observed that mean serum IGF-I levels
in nephrotic serum were slightly decreased. However, there was a
considerable variability from clearly decreased to increased serum
levels. Mean serum IGF-II levels were slightly increased. Two
previous studies have examined serum IGF levels in children with
the nephrotic syndrome. Garin, Grant and Silverstein [331 re-
ported a —50% reduction of serum IGF-I and a —60% of serum
IGF-1I in children with the nephrotic syndrome compared with
matched controls. Lee, Park and Kim [34] observed a —60%
reduction of serum IGF-I, but did not measure serum IGF-II. The
reason for the somewhat different results in our study may involve
differences in the patient population regarding the degree or the
duration of the nephrotic syndrome, the selectivity of the protein-
uria or a combination of these factors. The main stimulatory
regulators of serum IGF-I levels in humans are the GH secretory
status and the nutritional supply. Both calorie and protein mal-
nutrition reduce circulating IGF-I levels [351 A better nutritional
status of the patients in our study who were closely supervised by
a dietitian might explain the higher circulating IGF-l levels than in
the two previous reports. Serum GH levels are less likely to play
a role, because children with the nephrotic syndrome have normal
basal and peak GH levels to insulin provocation [36] and a normal
spontaneous GH secretory pattern [37].
Also, differences in the assay technique may play a role. In
particular in conditions where serum IGFBP concentrations are
high, such as chronic renal failure, it is important to remove
IGFBPs from the sample prior to assay, because residual IGFBP
in the assay mixture can interfere with antibody binding [18, 38].
We have previously shown that the most reliable estimates of IGF
levels in biological fluids can be obtained by blocking residual
IGFBPs in the assay mixture with excess of IGF-I or IGF-II,
respectively [18].
In the setting of experimental nephrotic syndrome, similarly
inconsistent results about serum IGF-I levels were reported. In
one study in puromycin-induced nephrosis in the rat [39], serum
IGF-I levels were normal compared to pair-fed controls, but
hepatic IGF-I mRNA levels were decreased by —50%. In con-
trast, a second study in adriamycin-induced nephrosis in rats [40]
demonstrated a reduction of serum IGF-I levels by —40%, but
hepatic IGF-I mRNA was unchanged. Hence, there is clearly a
considerable biological variability in serum IGF-I levels in the
setting of clinical and experimental nephrotic syndrome that is
most likely due to differences in the production rate, transcapillaiy
movement and urinary losses of the peptide.
Our study is the first that also quantified the urinary losses of
IGFs in patients with the nephrotic syndrome. We report a
fivefold increase of urinary IGF-I and IGF-Il excretion compared
with matched controls that is most likely due to increased
glomerular permeability to these peptides. The comparable ratio
of IGF-II over IGF-I in nephrotic and control urine might
indicate that a potentially altered renal production of IGFs does
not contribute significantly to the urinary losses of IGFs in the
nephrotic syndrome. The urinary losses of IGFs occur in the
presence of a 12-fold increase of IGFBP-1 and a twofold increase
of IGFBP-2 and -3 excretion in the urine. Whether the increased
glomerular ultrafiltration of IGFs in the nephrotic syndrome
exerts any biological effect in the kidney is not known. Feld and
Hirschberg [41] have suggested that the exposure of apical tubule
receptors to supraphysiological IGF-I in nephrotic urine may
contribute to increased phosphate retention and increase the
expression of extracellular matrix genes, thereby contributing to
the interstitial fibrosis that is sometimes observed in chronic
nephrotic glomerulopathies.
IGF serum levels must be interpreted in relation to their
respective serum IGFBP levels. We report for the first time a
marked increase of serum IGFBP-1 levels in children with the
nephrotic syndrome despite a 12-fold increase of urinary IGFBP-1
excretion. Because circulating IGFBP-l is mainly produced in
liver tissue, the constellation of increased IGFBP-1 serum levels
despite enhanced urinary losses of the protein indicates increased
hepatic production. This hypothesis remains to be tested in
experimental studies. We also report for the first time by RIA a
pronounced increase of IGFBP-2 in nephrotic serum despite a
twofold increased urinary excretion rate of the protein. Lee et al
[34] had previously assumed increased IGFBP-2 levels in ne-
phrotic children by use of Western ligand blots. The mechanism
for increased IGFBP-2 levels in the nephrotic syndrome is most
likely increased hcpatic production, because there was a fourfold
increase of liver IGFBP-2 mRNA in experimental nephrosis [40].
The specific stimulus for increased hepatic production of
IGFBP-2 and, most likely, also of IGFBP-1 in the nephrotic
syndrome remains to be elucidated. Calorie and protein malnu-
trition is not likely to play a role in our study, as indicated above.
It is noteworthy that in humans prolonged fasting over nine days
is needed to cause an increase in serum IGFBP-2 levels [42]. In
our study, IGFBP-2 levels were closely related to the degree of the
nephrotic syndrome, as estimated by serum albumin levels. How-
ever, the specific metabolic link between these two parameters
remains to be elucidated.
We report an increase of serum IGFBP-3 by RIA in the
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Table 3. Urinary excretion rates (U) of IGFs and IGFBPs in children with active ncphrotic syndrome and age-matched controls
Fig. 7. Representative elution profiles of
immunoreactive IGFBP.3 in normal urine (N =
5) (straight line) and in two children with
active nephrotic syndrome by FPLC. Nearly
identical results were obtained for the elution
profiles of urinary IGFBP-3 in the five controls
tested (r = 0.97), and therefore, only mean
values are shown. Both in control and nephrotic
urine, immunoreactive IGFBP-3 eluted at a mol
wt below 60 kDa with a peak at 20 kDa,
representing intact IGFBP-3 (40 to 50 kDa)
and low molecular weight IGFBP-3 fragments.
ALS is a glycoprotein of —85 kDa that combines with the
GH-dependent IGFBP-3 and IGF-I or IGF-Il to form the 150
kDa IGFBP complex [4]. Two thirds of the total ALS in serum is
present in the -150 kDa complex, and one third is uncomplexed
[25]. We observed normal serum levels of ALS in the nephrotic
syndrome, indicating that the decrease of the 150 kDa IGFBP
complex in nephrotic serum is not due to a deficiency of ALS.
We report normal levels of the high-affinity GHBP in nephrotic
serum. Because GHBP in humans is thought to reflect GH
receptor status in GH target tissues [13], this finding indicates
normal tissue density of GH receptors in patients with the
nephrotic syndrome. In contrast, Thabet et a! [39] suggested by
semiquantitative estimations of hepatic GH receptor mRNA
levels that hepatic GH receptor density is low in experimental
purimycin-induced nephrosis.
Our data can be summarized as follows: Serum IGF-l levels in
the setting of clinical nephrotic syndrome are slightly decreased,
whereas IGF-II levels are slightly increased, resulting in normal
total serum IGF levels. However, the binding of IGFs to IGFBPs
in the circulation is altered. There is a clear-cut increase of serum
IGFBP-1 and a pronounced increase of serum IGFBP-2, whereas
the high molecular weight IGFBP ternary complex is decreased in
nephrotic serum. In the presence of normal ALS concentrations,
this alteration is most likely due to an increased proteolytic
degradation of intact IGFBP-3. The shift of bound IGFs from the
U-IGF-I
ng/m2/day(N = 16)
U-IGF-11
ng/m2/day(N = 16)
U-IGFBP-1
pg/m2/day(N = 10)
U-IGFBP-2
pglm2lday(N = 10)
U-IGFBP-2
pg/m2/day(N = 25)
68.8 (13.0—282)Nephrotic syndrome 497 (84—3070) 6040 (1770—13,500) 44.1 (21.9—69.4) 30.7 (8.1-182)
Controls (N = 12) 83 (25—124) 1157 (612—1662) 3.6 (0.3—11.8) 15.4 (6.6—36.5) 28.2 (16. 1—43.8)
Statistics P < 0.0001 P < 0.0001 P < 0.001 P < 0.01 P < 0.005
Data are median (range).
Significant difference between patients with active nephrotic syndrome and controls
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nephrotic syndrome in the presence of a twofold increased urinary
excretion rate. FPLC analysis showed that the increase of immu-
noreactive IGFBP-3 in nephrotie syndrome is due to increased
levels of low molecular weight IGFBP-3 fragments, whereas the
intact 150 kDa IGFBP-3 ternary complex was clearly reduced and
the binding of IGF-I to low molecular weight IGFBPs was clearly
increased. Lee et a! [34] reported a decrease of intact IGFBP-3 by
Western ligand blotting in children with the nephrotic syndrome.
The reason for decreased intact IGFBP-3 in nephrotie serum is
not entirely clear. We did not detect increased protease activity
towards IGFBP-3 in nephrotie serum; however, we cannot ex-
clude that the proteolytic activity was too low in serum to be
detected by our assay. In the experimental nephrotic syndrome,
Hirsehberg and Kaysen [40] reported decreased intact IGFBP-3
by Western ligand blot and Western immunoblot and an increased
protease activity towards rhIGFBP-3 in nephrotie urine, but not in
serum.
We demonstrated by FPLC analysis that nephrotic urine con-
tains IGFBP-3 with a molecular mass between —45 kDa (intact
IGFBP-3) and —15 kDa, most likely representing low molecular
weight IGFBP-3 fragments. The difference between this and the
observation of Garin, Grant and Silverstein [33], who showed in
gel filtration and binding studies with iodinated IGFs the presence
of the 150 kDa complex in nephrotie urine, might be due to
differences in the permseleetivity of the proteinuria.
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Fig. 8. Serum ALS levels in children with active nephrotic syndrome
related to the age-dependent normal range (mean 2 su). Closed symbols
indicate patients with serum albumin levels below 25 g/liter, open symbols
above 25 g/liter.
150 kDa complex that is restricted to the circulation to low
molecular weight IGFBPs should on the one hand facilitate the
transepithelial transport of IGFs to IGF target tissues. On the
other hand, the excess of unsaturated high-affinity IGFBPs in
nephrotic serum has the ability to inhibit IGF action on target
tissues by competing with the type I IGF receptor for IOF
binding. Hence, it is likely that the altered IGF/IGFBP system in
nephrotic serum results in decreased IGF action in target tissues,
thereby contributing to catabolism and growth failure in the
nephrotic state.
Reprint requests to Burkhard TonshoJf M.D., Division of Pediatric Ne-
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